Home » Blog » Targeting ESE3/EHF with Nifurtimox inhibits CXCR2+ neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy

Blog

Targeting ESE3/EHF with Nifurtimox inhibits CXCR2+ neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy

reviewer4you.com

4 April 2024

0 Views 0

SaveSavedRemoved 0

Since pancreatic cancer responds poorly to chemotherapy and immunotherapy, it is necessary to identify novel targets and compounds to overcome resistance to treatment.